Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate

Sleep

Volumn 29, Issue 8, 2006, Pages 1025-1029

  Murali, Hema ^a   Kotagal, Suresh ^a,b  

^a MAYO CLINIC   (United States)

^b Division of Child Neurology   (United States)

Author keywords

Cataplexy; Gamma hydroxy butyrate; Narcolepsy; Sodium oxybate; Treatment; Xyrem

Indexed keywords

4 HYDROXYBUTYRIC ACID; OXYBATE SODIUM;

ADOLESCENT; CATAPLEXY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; MALE; NARCOLEPSY; NIGHT SLEEP; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; RETROSPECTIVE STUDY; REVIEW;

EID: 33747517239     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/29.8.1025     Document Type: Review

References (22)

1. Hublin C, Partinen M, Kaprio J, Koskenvuo M, Guilleminault C. Epidemiology of narcolepsy. Sleep 1994;17:S7-12.
2. Challamel MJ, Mazzola ME, Nevsimalova S, Cannard C, Louis J, Revol M. Narcolepsy in children. Sleep 1994;17:817-20
3. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 2004;8:355-66.
4. Ivanenko A, Tauman R and Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003;4:579-82.
5. Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996;5:217.
6. Larrosa O, de la Llave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001;24:282-5.
7. Guilleminault C, Mancuso J, Salva MA, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1986;9:275-9.
8. Parkes JD, Schachter M. Clomipramine and clonazepam in cataplexy. Lancet 1979;2:1085-6.
9. Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003;4:1165-74.
10. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17:113-6.
11. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J 2003;17:1691-703.
12. US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9.
13. rd. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25:29-34.
14. Maitre M. The γ-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997;5:337-61.
15. Mamelak M, Escriu JM, Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 1977;12:273-88.
16. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997;100:745-53.
17. Product labeling. Xyrem (sodium oxybate) oral solution. Orphan Medical, Inc.
18. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23.
19. MW Johns. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
20. Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998;24:179-83.
21. Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005;28:754-63.
22. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21.